Leading US Based Pharmaceutical Selects OmniComm's TrialMaster For A Phase III International Study

Fort Lauderdale, FL - OmniComm Systems, Inc., a global provider of eClinical solutions, announced recently that it was selected by a leading pharmaceutical company to provide OmniComm's flagship EDC Solution, TrialMaster, for a Phase III study of a drug to test a central nervous system disorder. The contract is for in excess of $200,000 and total revenue generated from this customer exceeds $750,000 over the last six months.

"OmniComm continues to enhance clinical trial outcomes through TrialMaster," said Stephen Johnson, COO of OmniComm Systems. "We are gratified that another customer has entrusted us with managing their data in a pivotal study. Our ability to attract and retain leading pharmaceutical companies has contributed to a strong start in 2010."

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large-scale institutions to efficiently capitalize on their clinical research investments. OmniComm Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

SOURCE: OmniComm Systems, Inc.